CD79b molecule, immunoglobulin-associated beta, also known as CD79B (Cluster of Differentiation 79B), is a human gene. [5] It is associated with agammaglobulinemia-6. The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig).

CD79a and CD79b are both members of the immunoglobulin superfamily. Human CD79a is encoded by the mb-1 gene that is located on chromosome 19, and CD79b is encoded by the B29 gene that located on chromosome 17.

2024年12月24日 · CD79B (CD79b Molecule) is a Protein Coding gene. Diseases associated with CD79B include Agammaglobulinemia 6, Autosomal Recessive and Agammaglobulinemia 6. Among its related pathways are Autodegradation of the E3 …

CD79B is a prognostic marker in Cervical squamous cell carcinoma and endocervical adenocarcinoma, Head and neck squamous cell carcinoma, Kidney renal clear cell carcinoma, Kidney renal papillary cell carcinoma, Lung adenocarcinoma

2023年11月2日 · Introduction: CD79B is a target of polatuzumab vedotin, an antibody-drug conjugate, which significantly improved the prognosis of both previously untreated and relapsed/refractory patients with diffuse large B-cell lymphoma (DLBCL).

2017年1月11日 · The signal transduction molecule CD79B plays a critical role in B-cell receptor (BCR) expression. CD79B forms a disulfide-linked heterodimeric complex with CD79A that escorts the immunoglobulin mu (IgM) heavy chain (IGHM; 147020) to …

2008年11月16日 · The primary aims of our research were: 1) to determine progression-free survival (PFS) and overall survival (OS) upon CD79b expression; 2) whether CD79b could predict varied outcome within ZAP-70+ and ZAP-70 negative subgroups; and finally 3) whether CD79b was an independent prognostic factor.

2007年7月15日 · We show here that the stable-linker ADCs anti-CD79b-MCC-DM1 and anti-CD79b-MC-MMAF are capable of target-dependent killing of nonHodgkin lymphoma cell lines in vitro.

2024年11月26日 · CD79b, a B-cell-specific antigen, is highly expressed in mature B-cell lymphomas, making it a promising therapeutic target. This study employs flow cytometry to assess CD79b in lymph node biopsies from 127 cases of large B-cell lymphomas (LBCLs), compared to benign reactive hyperplasia.

2021年5月14日 · B cell lymphoma and lymphoproliferative disorders: CLL (18%, Arch Pathol Lab Med 2003;127:561), CLL with IgM paraproteins (58%, Am J Clin Pathol 2005;123:594) and lymphoplasmacytic lymphoma (85%, Am J Clin Pathol 2005;124:414)